2-yr relativity-047: nivolumab relatlimab in previously untreated metastatic/unresectable melanoma
Published 7 months ago • 209 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
6:17
relativity-047: relatlimab, an anti-lag-3 antibody nivolumab in first-line advanced melanoma
-
7:09
relativity-047: relatlimab (rela) plus nivolumab (nivo) versus nivo in first-line advanced melanoma
-
6:19
should you treat melanoma with nivolumab and relatlimab (opdualag)?
-
2:01
elucidating biomarkers of response in the relativity-047 trial
-
0:46
the benefits of nivolumab and relatlimab in melanoma
-
5:01
melanoma highlights from esmo 2021
-
0:37
what is the best sequence of treatment for metastatic melanoma?
-
2:22
adjuvant nivolumab in patents with high-risk resected melanoma
-
2:45
long-term outcomes of nivo vs. nivo/ipi in melanoma brain metastases: abc trial data
-
2:54
combining nivolumab and ipilimumab in patients with resected stage iv melanoma
-
2:32
current status of immunotherapy for advanced melanoma
-
0:45
immunotherapy basics in melanoma
-
1:13
checkmate 067: nivolumab plus ipilimumab combination therapy in advanced melanoma
-
1:07
dr. lynn schuchter discusses two trials looking at nivolumab in melanoma
-
1:00
dana monroe discusses ipilimumab's side effects
-
2:19
immunotherapy and advances in melanoma | upmc video rounds
-
1:43
future directions in melanoma
-
1:04
the safety of nivolumab for advanced melanoma
-
1:15
unmet needs in melanoma